| REPLIMUNE GROUP INC. |
| USA |
| Gesundheit |
| US76029N1063 / A2JQN1 |
| 7R8 (Frankfurt) / REPL (NASDAQ) |
| FRA:7R8, ETR:7R8, 7R8:GR, NASDAQ:REPL |
| - |
| https://replimune.com/ |
|
Replimune Group Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing oncolytic immunotherapies for cancer treatment. Its proprietary product candidates harness oncolytic viruses to selectively replicate in and de..
>Volltext.. |
| 716.23 Mio. EUR |
| 580.03 Mio. EUR |
| - |
| -277 Mio. EUR |
| -276.08 Mio. EUR |
| -3.08 EUR |
| 98.13 Mio. EUR |
| 183.82 Mio. EUR |
| -246.53 Mio. EUR |
| 4.62 |
| - |
| -18.87% |
| - |
| - |
| - |
| - |
| REPLIMUNE |
| 28.07.26 |